Literature DB >> 2561189

The in-vitro antifungal spectrum of itraconazole.

J Van Cutsem.   

Abstract

The activity of itraconazole on 6113 fungal strains belonging to 252 species was evaluated in fluid media. The test medium was brain heart infusion broth for all fungi, except for Pityrosporum ovale, for which it was Dixon broth. Most of the human and animal pathogens and a large number of saprophytes were highly sensitive: dermatophytes, Candida, Cryptococcus, Torulopsis, Pityrosporum, Aspergillus, Penicillium, Sporothrix, dimorphic fungi, phaeohyphomycetes, agents of eufungal mycetoma, Entomophtorales and various others. The majority of Fusarium species and the Zygomycetes were poorly sensitive. Itraconazole was not only fungistatic at low concentrations, but also fungicidal for the tested organisms, such as Microsporum canis, Trichophyton mentagrophytes, Candida albicans, C. tropicalis, Aspergillus fumigatus, P. ovale and Cryptococcus neoformans with or without replenishment. Itraconazole was able to block the morphogenetic transformation of C. albicans from the yeast phase into the (pseudo)-mycelium phase.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2561189

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  7 in total

1.  Efficacy of the cyclodextrin liquid preparation of itraconazole in treatment of denture stomatitis: comparison with itraconazole capsules.

Authors:  L J Cross; J Bagg; T C Aitchison
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients.

Authors:  Timothy H Waterhouse; Stefanie Redmann; Stephen B Duffull; John A Eccleston
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

3.  A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients.

Authors:  Stefanie Hennig; Timothy H Waterhouse; Scott C Bell; Megan France; Claire E Wainwright; Hugh Miller; Bruce G Charles; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2006-10-30       Impact factor: 4.335

4.  Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients.

Authors:  Stefanie Hennig; Claire E Wainwright; Scott C Bell; Hugh Miller; Lena E Friberg; Bruce G Charles
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Utility of inoculum counting (Walshe and English criteria) in clinical diagnosis of onychomycosis caused by nondermatophytic filamentous fungi.

Authors:  A K Gupta; E A Cooper; P MacDonald; R C Summerbell
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

Review 6.  The therapeutic monitoring of antimicrobial agents.

Authors:  E J Begg; M L Barclay; C J Kirkpatrick
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

7.  New in vitro assay based on glucose consumption for determining intraconazole and amphotericin B activities against Aspergillus fumigatus.

Authors:  J C Garrigues; G Cadet de Fontenay; M D Linas; M Lagente; J P Seguela
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.